Premier Research: CAR T-Cell Therapy Insights Recognized at ISPOR Europe

CAR T-cell therapy is an innovative treatment approach for certain cancers, but its high cost and specialized administration requirements may limit access for many patients in real-world settings.

New Premier research, featured in this year’s ISPOR Europe Oncology poster tour, analyzed U.S. CAR T-cell therapy utilization trends and possible factors limiting access to this leading-edge treatment approach.

The Premier study was recognized as a top 5 percent finalist in the ISPOR Europe 2024 Research Presentation Awards.

Methodology

The retrospective observational study utilized the Premier Healthcare Database (PHD) for the period from January 1, 2017, to March 31, 2024. Accounting for 25 percent of the nation’s inpatient and outpatient discharges, the PHD is the largest hospital discharge database in the U.S.

The study team assessed yearly CAR T-cell therapy utilization trends. Researchers also analyzed demographic and hospital characteristics of 1,781 patients receiving CAR T-cell therapy (0.36 percent) compared to those of the overall study group diagnosed with multiple myeloma, large B-cell lymphoma, lymphoid leukemia, follicular lymphoma or mantle cell lymphoma.

Results

• The study showed an increasing trend of CAR T-cell therapy utilization from 2017 to 2023, especially for large B-cell lymphoma and multiple myeloma.

• Treatments were concentrated in large, urban and teaching hospitals, indicating geographical and institutional differences that can limit access for patients in rural or underserved areas.

• Older, female and Black patients were underrepresented among CAR T-cell recipients. Uninsured patients were also less likely to receive CAR T-cell therapy, highlighting potential economic barriers and emphasizing the importance of equitable access.

Specific findings shed light on differences in CAR T-cell therapy utilization based on age, gender, race, payer type, hospital size, hospital type and geographic location. The data may help inform future strategies to improve access to these treatments in real-world settings.

Premier’s best-in-class database provides deep, actionable insights that are not available through regular claims databases. With extensive experience in study design and data analysis, the Premier research team uses this real-world evidence to solve real-world issues and support healthcare transformation.

ISPOR, or The Professional Society for Health Economics and Outcomes Research, is a critical catalyst for advancing the science and practice of health economics and outcomes research on a global scale – and ISPOR Europe is one of the discipline’s most important and largest events.

Learn More:

• Learn how Premier’s partnerships, real-world data and AI technology are helping expand access to cancer clinical trials.

• Explore how Premier’s prospective research and clinical trial capabilities can benefit your organization.

• Get your copy of a new e-book with specific strategies healthcare organizations can use to tackle today’s biggest data and technology challenges.